Clinical Trial to Evaluate the Effect on the Pharmacokinetic Characteristics of HCP1007 Capsule

Hanmi Pharmaceutical Company Limited28 enrolled

Overview

The purpose of this study is to evaluate pharmacokinetics and safety after oral administration of HCP1007 capsules and Rosuvastatin plus Omega-3.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Healthy

Interventions

HCP1007 / omarco and crestorDRUG

HCP1007 / Rosuvastatin plus Omega-3

Eligibility

Sex: MALEMin age: 20 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy male volunteers, age between 20 and 45 * Informed of the investigational nature of this study and voluntarily agree to participate in this study * BMI of \>20kg/m2 and \<26kg/m2 subject Exclusion Criteria: * Use of any prescription medication within 14 days prior to Day 1 * Use of any medication within 7 days prior to Day 1 * Participation in another clinical study within 60 days prior to start of study drug administration

Locations (1)

Asan Medical Center

Seoul, South Korea

Outcomes

Primary Outcomes

Area Under Curve(AUC) last

Time frame: 0,0.5,1,1.5,2,2.5,3,4,5,6,9,12,24,48hours post-dose

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.